DE602006019880D1 - Verwendung von thienopyridonderivaten als ampk-aktivatoren und pharmazeutische zusammensetzungen, die diese enthalten - Google Patents

Verwendung von thienopyridonderivaten als ampk-aktivatoren und pharmazeutische zusammensetzungen, die diese enthalten

Info

Publication number
DE602006019880D1
DE602006019880D1 DE602006019880T DE602006019880T DE602006019880D1 DE 602006019880 D1 DE602006019880 D1 DE 602006019880D1 DE 602006019880 T DE602006019880 T DE 602006019880T DE 602006019880 T DE602006019880 T DE 602006019880T DE 602006019880 D1 DE602006019880 D1 DE 602006019880D1
Authority
DE
Germany
Prior art keywords
pharmaceutical compositions
compositions containing
ampk activators
thienopyridone derivatives
thienopyridone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602006019880T
Other languages
English (en)
Inventor
Sophie Hallakou-Bozec
Christine Charon
Bjoern Hock
Oliver Poeschke
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Patent GmbH
Original Assignee
Merck Patent GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent GmbH filed Critical Merck Patent GmbH
Publication of DE602006019880D1 publication Critical patent/DE602006019880D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
DE602006019880T 2005-08-18 2006-07-03 Verwendung von thienopyridonderivaten als ampk-aktivatoren und pharmazeutische zusammensetzungen, die diese enthalten Active DE602006019880D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05291753A EP1754483A1 (de) 2005-08-18 2005-08-18 Verwendung von Thienopyridonederivativen als AMPK Aktivatoren und pharmazeutische Zusammensetzungen, die diese enthalten
PCT/EP2006/006446 WO2007019914A1 (en) 2005-08-18 2006-07-03 Use of thienopyridone derivatives as ampk activators and pharmaceutical compositions containing them

Publications (1)

Publication Number Publication Date
DE602006019880D1 true DE602006019880D1 (de) 2011-03-10

Family

ID=35636709

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602006019880T Active DE602006019880D1 (de) 2005-08-18 2006-07-03 Verwendung von thienopyridonderivaten als ampk-aktivatoren und pharmazeutische zusammensetzungen, die diese enthalten

Country Status (20)

Country Link
US (1) US20090105293A1 (de)
EP (2) EP1754483A1 (de)
JP (1) JP5161774B2 (de)
KR (1) KR20080034491A (de)
CN (1) CN101232883A (de)
AT (1) ATE496622T1 (de)
AU (1) AU2006281761B2 (de)
BR (1) BRPI0614828A2 (de)
CA (1) CA2619505C (de)
CY (1) CY1111660T1 (de)
DE (1) DE602006019880D1 (de)
DK (1) DK1915150T3 (de)
ES (1) ES2359860T3 (de)
MX (1) MX2008002062A (de)
PL (1) PL1915150T3 (de)
PT (1) PT1915150E (de)
RU (1) RU2416409C2 (de)
SI (1) SI1915150T1 (de)
WO (1) WO2007019914A1 (de)
ZA (1) ZA200802454B (de)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102005017152B4 (de) * 2005-04-13 2007-02-08 Lindauer Dornier Gmbh Verfahren zum Trocknen von vorzugsweise plattenförmigen Produkten und Durchlauftrockner in Mehretagenbauweise
CA2699157A1 (en) 2007-09-10 2009-03-19 Calcimedica, Inc. Compounds that modulate intracellular calcium
WO2009124636A1 (en) * 2008-04-11 2009-10-15 Merck Patent Gmbh Thienopyridone derivatives as amp-activated protein kinase (ampk) activators
CA2723429C (en) * 2008-05-05 2016-10-11 Daniel Cravo Thienopyridone derivatives as amp-activated protein kinase (ampk) activators
GB0813403D0 (en) 2008-07-22 2008-08-27 Lectus Therapeutics Ltd Potassium ion channel modulators & uses thereof
MY157445A (en) 2008-08-27 2016-06-15 Calcimedica Inc Compounds that modulate intracellular calcium.
US8524763B2 (en) 2008-09-22 2013-09-03 Calcimedica, Inc. Inhibitors of store operated calcium release
WO2010103040A1 (en) 2009-03-10 2010-09-16 INSERM (Institut National de la Santé et de la Recherche Médicale) 5'-adenosine monophosphate-activated protein kinase (ampk) activators for treating pulmonary hypertension
KR101062670B1 (ko) * 2009-06-01 2011-09-06 (주)아모레퍼시픽 2,5-비스-아릴-3,4-디메틸테트라하이드로퓨란 리그난을 유효성분으로 포함하는 에이엠피케이의 활성화에 의해 매개되는 비만 관련 질환의 예방 또는 치료용 조성물
WO2011034962A2 (en) 2009-09-16 2011-03-24 Calcimedica Inc. Compounds that modulate intracellular calcium
CN102666485A (zh) * 2009-09-21 2012-09-12 霍夫曼-拉罗奇有限公司 烯烃羟吲哚衍生物及其用于治疗肥胖症，糖尿病和高脂血症的应用
US20130085169A1 (en) 2010-04-02 2013-04-04 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and compositions comprising ampk activator (metformin/troglitazone) for the treatment of myotonic dystrophy type 1 (dm1)
MX337711B (es) 2010-08-27 2016-03-15 Calcimedica Inc Compuestos que modulan el calcio intracelular.
EP2611801B1 (de) * 2010-09-01 2016-05-04 Bayer Intellectual Property GmbH Herbizid wirksame ketosultame und diketopyridine
US9005909B2 (en) 2011-01-06 2015-04-14 Rigel Pharmaceuticals, Inc. Whole blood assay for measuring AMPK activation
JP2014507452A (ja) * 2011-03-07 2014-03-27 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー キノリン誘導体
US8889730B2 (en) 2012-04-10 2014-11-18 Pfizer Inc. Indole and indazole compounds that activate AMPK
EP2679591A1 (de) 2012-06-29 2014-01-01 Poxel Thienopyridon-Derivate zur Verwendung als AMPK-Aktivatoren
US9512116B2 (en) 2012-10-12 2016-12-06 Calcimedica, Inc. Compounds that modulate intracellular calcium
US9394285B2 (en) 2013-03-15 2016-07-19 Pfizer Inc. Indole and indazole compounds that activate AMPK
WO2015103480A1 (en) 2014-01-02 2015-07-09 Massachusetts Eye & Ear Infirmary Treating ocular neovascularization
CN105315275B (zh) * 2014-07-14 2019-10-01 中国科学院上海药物研究所 一类吡唑酮化合物及其用途
EP3355876A2 (de) 2015-09-30 2018-08-08 Instituto de Medicina Molecular Verfahren zur abschwächung der virulenz von parasiten
EP3478297A1 (de) 2016-06-30 2019-05-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Verfahren und pharmazeutische zusammensetzungen zur behandlung von kardiomyopathien
KR20190096949A (ko) 2016-10-05 2019-08-20 유니버시티 오브 피츠버그 - 오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션 소분자 ampk 활성화제
AU2018225074B2 (en) 2017-02-22 2022-04-21 Universite Du Havre Compounds and methods for inhibiting EMT pathways to treat cancer, organ fibrosis and metabolic disorders
SG11202104813VA (en) * 2018-11-16 2021-06-29 Poxel Monohydrate potassium salt of a thienopyridone derivative and its preparation process
WO2020201263A1 (en) 2019-04-01 2020-10-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment and prevention of cardiac remodeling
WO2022106892A1 (en) 2020-11-17 2022-05-27 Instituto De Medicina Molecular Anti-malarial compounds

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8625941D0 (en) * 1986-10-30 1986-12-03 Sandoz Ltd Substituted alpha-amino acids
DE4444815A1 (de) * 1994-12-15 1996-06-20 Merck Patent Gmbh Thienopyridone
FR2846656B1 (fr) 2002-11-05 2004-12-24 Servier Lab Nouveaux derives d'imidazopyridine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US7119205B2 (en) 2003-05-16 2006-10-10 Abbott Laboratories Thienopyridones as AMPK activators for the treatment of diabetes and obesity
JP2005089384A (ja) 2003-09-18 2005-04-07 Kao Corp 持久力向上剤

Also Published As

Publication number Publication date
PL1915150T3 (pl) 2011-05-31
ATE496622T1 (de) 2011-02-15
WO2007019914A1 (en) 2007-02-22
RU2416409C2 (ru) 2011-04-20
AU2006281761A1 (en) 2007-02-22
CA2619505A1 (en) 2007-02-22
RU2008109914A (ru) 2009-09-27
CY1111660T1 (el) 2015-10-07
AU2006281761B2 (en) 2012-01-19
US20090105293A1 (en) 2009-04-23
KR20080034491A (ko) 2008-04-21
JP5161774B2 (ja) 2013-03-13
MX2008002062A (es) 2008-04-16
CN101232883A (zh) 2008-07-30
ZA200802454B (en) 2009-01-28
EP1754483A1 (de) 2007-02-21
ES2359860T3 (es) 2011-05-27
CA2619505C (en) 2015-04-28
EP1915150B1 (de) 2011-01-26
DK1915150T3 (da) 2011-02-21
JP2009504693A (ja) 2009-02-05
PT1915150E (pt) 2011-05-02
SI1915150T1 (sl) 2011-04-29
EP1915150A1 (de) 2008-04-30
BRPI0614828A2 (pt) 2011-04-19

Similar Documents

Publication Publication Date Title
DE602006019880D1 (de) Verwendung von thienopyridonderivaten als ampk-aktivatoren und pharmazeutische zusammensetzungen, die diese enthalten
DE602006009095D1 (en) Diacylglycerol-acyltransferase-hemmer
NO20085066L (no) 4,5-difenyl-pyrimidinyl-aminosubstituerte karboksylsyrer, fremgangsmate for deres fremstilling og anvendelse derav som medikamenter
NO20085067L (no) 4,5-difenyl-pyrimidinyl substituerte karboksylsyrer, fremgangsmate for deres fremstilling og anvendelse derav som medikamenter
MX2007010532A (es) Derivados de amida de acido 1-sulfonil-piperidina-3-carboxilico como inhibidores de 11-beta-hidroxiesteroide deshidrogenasa para el tratamiento de diabetes mellitus tipo ii.
ATE397605T1 (de) Nebivolol und dessen pharmazeutisch unbedenkliche salze, herstellungsverfahren und pharmazeutische zusammensetzungen von nebivolol
SE0401971D0 (sv) Piperidne derivatives
WO2007082808A3 (en) Thiazoles as 11 beta-hsd1 inhibitors
NO20085064L (no) 4,5-difenyl-pyrimidinyl-oksy eller -merkaptosubstituerte karboksylsyrer, fremgangsmate for deres fremstilling og anvendelse derav som medikamenter
SG155961A1 (en) Pyrazoles as 11-beta-hsd-1
CY1112727T1 (el) Παραγωγα κυκλοβουτυλ αμινης βενζοθειαζολης και η χρηση αυτων ως προσδετες των υποδοχεων ισταμινης-3
AR054347A1 (es) Combinaciones terapeuticas para el tratamiento o la prevencion de la depresion
NO20054852L (no) GFAT inhibitorer
TW200643013A (en) Pyrazoles
NO20052683L (no) Nye pyridopyrimidinonforbindelser, fremgangsmate for deres fremstilling og farmasoytiske sammensetninger inneholdende dem
ECSP066883A (es) Derivados de heteroarilaminopirazol utiles para el tratamiento de la diabetes
DK2207770T3 (da) 1, 2, 3-triazolderivater til anvendelse som stearoyl-coa desaturase-inhibitorer
NO20085271L (no) Muscarin reseptoragonister som er effektive i behandling av smerte, Alzheimers sykdom og schizofreni
SE0401970D0 (sv) Novel compounds
BRPI0417858A (pt) composto, composição farmacêutica, e, uso de uma composição farmacêutica
GEP20094801B (en) Tetrazole derivatives and methods of treatment of metabolic-related disorders thereof
NO20070974L (no) Substituerte N-acyl-2-aminotiazoler
NO20080669L (no) Acetylenpiperaziner som metabotrofiske glutamatreseptorantagonister
NO20080671L (no) Bisykliske piperaziner som metabotrofiske glutamatreseptorantagonister
CO5690542A2 (es) Metodo para la produccion de derivados de acil-fenil-urea sustituidos por animo-carbonilo y el uso de los mismos